Vyvgart™ (efgartigimod alfa-fcab) – New orphan drug approval
On December 17, 2021, the FDA announced the approval of argenx’s Vyvgart (efgartigimod alfa-fcab), for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.
Download PDF
